Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial

BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study

Beacon raises $132M+ to bring AI-driven sleep diagnostics to masses

The device aims to bring precision neuroscience into clinical trials, accelerating drug development

Cardinal Health boosts production of cutting-edge cancer therapy ingredient

Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.

Clariant boosts US pharmaceutical production with Clear Lake expansion

The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production

Iza-bren delivers dual survival win in phase III trial for hard-to-treat breast cancer

Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival

BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints

Lupin launches Dasatinib tablets in US, eyes $930 million oncology market

Telangana unveils ambitious next-gen Life Sciences Policy at Davos

A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics

Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy

Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib

Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis

The company is excluding data from the affected sites to maintain the study's integrity